Description of Commitment

Transcription

1 U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / and /0 Description of A randomized, double-blind, placebocontrolled clinical trial to evaluate the effect of testosterone replacement therapy on the incidence of major adverse cardiovascular events in men. We recommend that this trial also assess other important safety and efficacy outcomes associated with testosterone therapy. A 10 year, observational study to prospectively evaluate the incidence of fibrosing colonopathy in patients with cystic fibrosis treated with Creon (pancrelipase) Delayed- Release Capsules in the US and to assess potential risk factors for the event. A 10 year, observational study to prospectively evaluate the risk of transmission of selected porcine viruses in patients taking Creon (pancrelipase) Delayed-Release Capsules. Establish a pregnancy registry of patients with rheumatoid arthritis who become pregnant while on anti-rheumatic therapy, including adalimumab as well as other medications, which will run for 3 years. February 09, 2015 April 30, 2009 April 30, June 30, 2022 June 20, 2021 June 20, 2021 Original : March 30, 2007 Extended: Pending Delayed

2 / Description of September 30, / / /110 Conduct Study Protocol P06-134, a 5-year, 5000 patient, multi-center, uncontrolled, observational study of adult patients with Crohn's disease treated in a routine clinical setting with adalimumab. Conduct Study Protocol P10-262, an 800- patient observational study, with inclusion of a reference group, of pediatric patients 4 to 17 years of age with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). Conduct a prospective, multi-center registry including 5000 adult psoriasis patients treated with adalimumab in the United States. This registry will characterize and assess the incidence of serious adverse events (including serious infections, tuberculosis, opportunistic infections, malignancies, hypersensitivity reactions, autoimmune reactions and deaths) as well as other adverse events of interest in the study cohort. All enrolled study patients will be evaluated for a period of at least 10 years February 27, 2007 February 21, 2008 January 18, 2008 Original : May 31, 2015 Extended: January 31, 2023 Delayed

3 / /274 Description of with comprehensive annual reports provided to the Agency. Collect data on the patient characteristics, demographics and drug exposure (including dose, duration and time to onset of adverse event). The collection of data will be via active surveillance methods and data will be validated by a review of medical records as per the guidance for industry titled Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. Enhanced pharmacovigilance program for reports of malignancy in pediatric, adolescent, and young adult (< 30 years of age) patients treated with adalimumab, for a period of up to 10 years after this notification to collect data that will be analyzed to better define the risk of this serious adverse event. The enhanced pharmacovigilance program includes the following: 1) active query of reporters to obtain additional clinical information related to malignancy diagnoses; 2) expedited reporting to of all initial and follow-up reports of any malignancy in pediatric and young adult patients. Interim analyses and summaries of new and November 02, 2011 March 31, 2020

4 / / /232 Description of cumulative safety information in pediatric and young adult patients must be submitted annually, followed by the final report at the conclusion of the monitoring period. Postmarketing Requirement (PMR) #1 - A study in inflammatory bowel disease (IBD) patients treated with Humira in which you will bank tissue or blood samples (as appropriate) and then analyze them to identify genetic mutations and other biomarkers that predispose these patients to developing Hepatosplenic T-Cell Lymphoma (HSTCL). Postmarketing Requirement (PMR) #2 - A multi-center observational study of Humira in adults with moderately to severely active ulcerative colitis treated in a routine clinical setting, to assess the longterm safety as measured by the incidence of opportunistic infections and malignancies. Long-term effectiveness should be assessed as a secondary goal. The proposed study should follow patients for a period of at least 10 years from time of enrollment in order to ascertain adverse events with longer latency periods such as malignancies. The primary September 28, 2012 September 28, 2012 September 30,

5 / /232 Description of analysis is to summarize safety data for patients on adalimumab and patients on nonbiologic immunomodulator therapy. The study should be adequately sized to sufficiently detect a doubling of the risk of lymphoma events in each treatment group. A secondary analysis is to summarize safety data for patients on adalimumab and patients on the combination of adalimumab and nonbiologic immunomodulator therapy. In addition, the study is to document and evaluate effects of withdrawal and retreatment with adalimumab and switching with other tumor necrosis factor (TNF)- blockers or biologics. Postmarketing Requirement (PMR) #3 - Develop, qualify, and implement improved validated anti-adalimumab antibody (AAA) assays with reduced sensitivity to product interference. Until assays have been developed and validated, patient blood samples collected from clinical studies and trials should be banked under appropriate storage conditions. You will provide assay SOPs, validation protocols, and validation final reports that include data demonstrating September 28, 2012 Original : 2013 Extended: September 30, Submitted

6 / / /232 Description of that the assay is specific, sensitive and reproducible, and capable of sensitively detecting AAA responses in the presence of adalimumab levels that are expected to be present at the time of patient sampling. Postmarketing Requirement (PMR) #4 - Utilizing a validated AAA assay as described in Postmarketing Requirement number 3 above, you should measure and analyze the immunogenicity profile based on post-dose patient samples from completed study M10-223, the trial conducted under Postmarketing Requirement number 5, the trial conducted under Postmarketing Requirement number 6, and the trial conducted under Postmarketing Requirement number 7. Postmarketing Requirement (PMR) #5 - Conduct a trial in moderately to severely active ulcerative colitis patients to evaluate the safety of induction regimens of adalimumab at doses higher than 160/80 mg. In this trial, the efficacy of Humira should also be assessed, both during induction treatment as well as during continued treatment after induction, and pharmacokinetic measurements should be September 28, 2012 September 28, 2012 March 31, 2019 March 31, 2019

7 / /232 Description of conducted for exposure-response analysis. In this trial, collecting samples for immunogenicity testing (utilizing a validated anti-adalimumab antibody assay as described in Postmarketing Requirement number 3 above) and conducting analyses of the impact of immunogenicity on safety, pharmacokinetics, and efficacy is important. Postmarketing Requirement (PMR) #6 - A safety and pharmacokinetic trial as a substudy of the trial described in Postmarketing Requirement number 5 above to evaluate trough concentrations of adalimumab and antibody levels (utilizing a validated antiadalimumab antibody assay as described in Postmarketing Requirement number 3 above) at the time of loss of clinical remission in patients whose physicians plan to escalate the dose (e.g., decrease the dosing interval to weekly or increase the dosage) in response to loss of remission. Trough concentrations will be evaluated to determine whether patients who have low adalimumab exposures benefit from dose escalation without increasing risk of serious adverse events. September 28, 2012 March 31, 2019 Postmarketing Requirement (PMR) #7 - September 28,

8 / Description of /232 Conduct a one-year, multi-center, randomized, double-blind placebo-controlled trial to evaluate the efficacy, safety and pharmacokinetics of adalimumab in pediatric patients 5 to 17 years of age with moderately to severely active ulcerative colitis. In this trial, the efficacy of adalimumab should be assessed during induction treatment as well as during continued treatment after induction, and pharmacokinetic measurements should be conducted for exposure-response analysis. Also, collect samples for immunogenicity testing (utilizing a validated AAA assay as described in Postmarketing Requirement number 3 above) and conduct analyses of the impact of immunogenicity on pharmacokinetics, efficacy and safety. KALETRA (lopinavir/riton avir) Please submit the 24 week results of PENTA 18 evaluating the pharmacokinetic, safety and activity of twice daily and once daily dosing of lopinavir/ritonavir tablets in a reviewable format. Submit a final report that includes detailed summaries of pharmacokinetic, safety and activity data as well as electronic datasets April 27, 2010 Original : 2013 Extended: September 30, Submitted

9 TRILIPIX (fenofibric acid) / Description of A randomized, double-blind, placebocontrolled trial evaluating the effect of fenofibric acid on the incidence of major adverse cardiovascular events in high-risk men and women at LDL-C goal on statin therapy, but with residually high triglycerides and low HDL-C Evaluate the pharmacokinetics, safety and treatment response (using sustained virologic response as the primary endpoint) of ombitasvir, paritaprevir, ritonavir, dasabuvir (Viekira Pak) in pediatric subjects 3 to less than 18 years of age with chronic hepatitis C virus infection Collect and analyze long-term safety data for subjects enrolled in the pediatric ombitasvir, paritaprevir, ritonavir, dasabuvir (Viekira Pak ) pharmacokinetic, safety, and antiviral efficacy study(ies). Data collected should include at least 3 years of follow-up in order to characterize the durability of response to ombitasvir, paritaprevir, ritonavir, dasabuvir (Viekira Pak ) and the long-term safety including growth assessment,sexual maturation, and characterization of resistance associated July 06, 2011 January 31, 2021 August 31, 2019 August 31, 2022 Delayed Pending Pending

10 / Description of substitutions in viral isolates from subjects failing therapy Conduct the following site-directed mutant HCV replicon phenotype analyses: Sofosbuvir activity against HCV replicons carrying NS5B substitutions associated with dasabuvir resistance: C316Y (GT1a and GT1b) and S556G (GT1a). Dasabuvir activity against HCV replicons carrying the following NS5B substitutions: L159F (GT1a and GT1b), V321A (GT1a and GT1b), M423I (GT1a), I482T (GT1a) and A486V (GT1b). Paritaprevir activity against HCV replicons carrying substitutions in the NS3 helicase (e.g., P334S, S342P, V406A/I, T449I, P470S) that emerged in virologic failure subjects treated with the 3-DAA ± RBV regimen; evaluate the impact of these substitutions alone and in combination with other key resistance-associated substitutions (e.g., R155K or D168x) that were often detected in combination Submit a final report for ongoing observational study M13-102, "A Follow-up Study to Assess Resistance and Durability of February 28, 2015 October 31, 2017 Fulfilled

11 / Description of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection." Conduct an observational study to investigate the safety and efficacy of ombitasvir, paritaprevir, ritonavir, dasabuvir (Viekira Pak ) in a sufficient number of Blacks/African Americans with and without cirrhosis compared to whites/caucasians Submit the final report and datasets for the ongoing clinical trial M entitled "An Open-Label Study to Evaluate the Safety and Efficacy of ABT- 450/Ritonavir/ABT-267 and ABT-333 with Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis." Submit the final report and datasets for the ongoing clinical trial M entitled "An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT- 450/Ritonavir and Dasabuvir with or without May 31, 2017 Pending

12 / Description of Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, with Severe Renal Impairment or End-Stage Renal Disease." Submit the final report and datasets for the ongoing Phase 3 clinical trial M entitled "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT- 450/Ritonavir/ABT-267 (ABT-450/r/ABT- 267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Submit the final report and datasets for the Phase 3 clinical trial M entitled "A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Experienced Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection." October 31, 2015 October 31, 2015

13 / Description of Submit the final report and datasets for the Phase 3 clinical trial M entitled "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT- 450/Ritonavir/ABT-267 (ABT-450/r/ABT- 267) and ABT- 333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis." Submit the final report and datasets for the Phase 3 clinical trial M entitled "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT- 450/Ritonavir/ABT-267 (ABT-450/r/ABT- 267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection." Submit the final report and datasets for the Phase 3 clinical trial M entitled "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT- 450/r/ABT-267) and ABT-333 With and September 30, 2015 September 30, 2015 October 31, 2015

14 / Description of Without Ribavirin in Treatment- Experienced Subjects with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection." Submit the final report and datasets for the Phase 3 clinical trial M entitled "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT- 450/Ritonavir/ABT-267 (ABT-450/r/ABT- 267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection." Submit the final report and datasets for the ongoing clinical trial M entitled "Open-label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 Hepatitis C Virus (HCV) Infection." Submit the final report and datasets for the ongoing clinical trial M entitled "A Randomized, Open-label Study September 30, 2015 February 21, 2018 June 30, 2018

15 ZEMPLAR (paricalcitol) ZEMPLAR (paricalcitol) / Description of to Evaluate the Safety and Efficacy of ABT- 450/Ritonavir/ABT-267 (ABT-450/r/ABT- 267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 (HIV-1) Coinfection." Submit the final report and datasets for the ongoing clinical trial M entitled "An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-50/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis." Deferred pediatric study under PREA for the treatment of Stage 3 and Stage 4 chronic kidney disease in pediatric patients ages twelve to sixteen years. Deferred pediatric study under PREA for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 5 for patients May 26, 2005 June 29, 2009 November 30, 2016 Original : 2008 Extended: June 20, 2015 Original : April 30, 2012 Extended: Delayed Delayed

16 ZEMPLAR (paricalcitol) / Description of receiving peritoneal dialysis in pediatric patients ages ten to sixteen years receiving peritoneal dialysis or hemodialysis. Deferred pediatric study under PREA for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 5 for patients receiving peritoneal dialysis in pediatric patients ages zero to nine years receiving peritoneal dialysis or hemodialysis. June 29, 2009 Note: The PMC Summary Table includes all active U.S. postmarketing commitments as of March 31, May 31, 2016 Original : April 30, 2012 Extended: May 31, 2020 Delayed